HydraFacial Wins Permanent Injunction in Skin Care Patent Battle

Introduction

In a decisive victory for the medical aesthetics industry, HydraFacial LLC and Edge Systems, LLC secured a judgment on the merits against MIRAmedtech SP. Z.O.O. and MIRAmedtech UG in the Central District of California (Case No. 8:24-cv-01865). Filed on August 26, 2024, and resolved by March 21, 2025 — just 207 days later — the court entered a permanent injunction barring the defendants from making, using, selling, or importing the MIRApeel systems into the United States.

The ruling, grounded in direct patent infringement under 35 U.S.C. § 271(a), covers four U.S. patents central to HydraFacial’s proprietary skin treatment technology. For IP professionals and patent litigators tracking aesthetics device patent litigation, this case offers a compelling study in rapid enforcement, international defendant exposure, and the strategic value of a robust patent portfolio. For R&D teams in the personal care and medical device sectors, it underscores the critical importance of freedom-to-operate (FTO) analysis before market entry.

Case Overview

The Parties

Patents at Issue

Four U.S. patents formed the basis of the infringement claims:

• • U.S. Patent No. 9,550,052 — foundational claims related to skin treatment system mechanics
• • U.S. Patent No. 11,446,477 — continuation claims covering operational methods or device configurations
• • U.S. Patent No. 11,865,287 — later-generation claims reflecting evolved system features
• • U.S. Patent No. 12,053,607 — most recent patent, reflecting continued prosecution strategy

Together, these patents represent a multi-generational portfolio spanning core and improvement claims — a hallmark of mature, well-managed IP strategy in the medical device sector.

The Accused Product

The MIRApeel system, distributed through eMIRAmed USA LLC, was accused of directly infringing all four patents. The complaint also referenced MIRAjolie cosmetic serums, suggesting the infringement extended to consumable components integral to the treatment system — amplifying the commercial stakes of the dispute.

Legal Representation

Plaintiffs were represented by Ali Razai, Benjamin J. Everton, and Christian D. Boettcher of Morgan, Lewis & Bockius, LLP — a firm with a recognized national patent litigation practice. No defendant legal representation was identified in the case record, a significant procedural note addressed below.

Litigation Timeline & Procedural History

The case was filed in the Central District of California, a venue with substantial IP docket experience and practical familiarity with technology-sector patent disputes. The 207-day resolution is notably swift by federal patent litigation standards, where cases routinely extend two to four years.

The absence of identified defense counsel in the case record is a critical procedural detail. It strongly suggests the defendant entities — particularly the foreign entities MIRAmedtech SP. Z.O.O. and MIRAmedtech UG — may have defaulted or declined to mount an active defense. This would explain both the accelerated timeline and the clean judgment on the merits in favor of the plaintiffs. For IP litigators, this pattern reflects a recurring challenge when foreign entities underestimate U.S. enforcement exposure.

The Verdict & Legal Analysis

Outcome

The court entered judgment on the merits in favor of HydraFacial LLC and Edge Systems, LLC against MIRAmedtech SP. Z.O.O. and MIRAmedtech UG on claims of direct patent infringement under 35 U.S.C. § 271(a). The judgment includes a permanent injunction prohibiting the defendants — and all persons acting in concert with them — from:

• 1. Making, using, selling, offering for sale, or importing the MIRApeel systems into the United States
• 2. Infringing U.S. Patent Nos. 9,550,052; 11,446,477; 11,865,287; and 12,053,607

No specific damages amount is disclosed in the available case record.

Verdict Cause Analysis

The legal basis is straightforward: direct infringement under 35 U.S.C. § 271(a), which requires that a party make, use, sell, offer to sell, or import a patented invention without authorization. The court’s issuance of a permanent injunction — rather than a damages-only remedy — signals a finding that monetary relief alone would be inadequate, consistent with the *eBay Inc. v. MercExchange* four-factor injunction standard.

Given the absence of defense counsel and the resulting judgment on the merits, this case likely proceeded through default judgment procedures or an uncontested motion. While the underlying claim construction and infringement analysis are not fully detailed in the available record, the breadth of the injunction — covering all four patents and binding third parties in active concert — reflects a comprehensive enforcement posture.

Legal Significance

This case reinforces several important principles:

• • Portfolio depth matters in enforcement. Four patents across multiple application numbers provide overlapping claim coverage, making design-arounds more difficult and judgment more comprehensive.
• • Permanent injunctions remain available in direct competitor disputes where irreparable harm and inadequate legal remedy are established — consistent with post-*eBay* jurisprudence in device markets.
• • Foreign entity exposure to U.S. injunctions is real and enforceable through import prohibitions and contempt mechanisms, even absent domestic assets.

Strategic Takeaways

For Patent Holders: Maintain continuation prosecution strategies to build layered claim portfolios. Early filing in the Central District of California can be advantageous for technology-sector plaintiffs seeking experienced IP courts. A permanent injunction is achievable — and powerful — in direct competitor contexts.

For Accused Infringers: Failure to engage U.S. counsel, particularly for foreign entities, creates default judgment risk. Even if the underlying device is manufactured abroad, U.S. sales and import activity create § 271(a) exposure. Design-around analysis should precede U.S. market entry, not follow litigation.

For R&D Teams: FTO analysis must address continuation families — not just issued patents. A cleared landscape based on one generation of patents may be obsolete within years as continuation applications mature. The inclusion of consumable serums as accused products also signals that FTO must extend to system components, not just hardware.

Industry & Competitive Implications

The medical aesthetics device sector is marked by high barriers to entry, significant capital expenditure, and intense IP competition. HydraFacial’s successful enforcement action reinforces its market position and sends a deterrent signal to international competitors considering U.S. distribution.

For competitors in the hydradermabrasion and skin resurfacing space, this verdict has immediate implications. The scope of the injunction — extending to importation — effectively closes the U.S. market to MIRApeel-type devices without a licensing arrangement or fundamental redesign. Companies marketing similar aesthetic platforms should review their IP clearance posture against HydraFacial’s active patent family.

From a licensing perspective, this outcome may prompt pre-litigation licensing inquiries from other market participants seeking to avoid similar enforcement. Patent holders in adjacent aesthetics technology spaces will note the speed and comprehensiveness of this enforcement action as a viable strategic model.

FAQ

What patents were involved in HydraFacial v. MIRAmedtech?

Four U.S. patents: Nos. 9,550,052; 11,446,477; 11,865,287; and 12,053,607, all covering aspects of HydraFacial’s skin treatment device technology.

What was the basis for the permanent injunction?

The court found direct patent infringement under 35 U.S.C. § 271(a) and entered judgment on the merits, granting permanent injunctive relief against the MIRAmedtech entities.

How might this verdict affect aesthetics device patent litigation?

It reinforces the viability of portfolio-based enforcement strategies and highlights import-ban exposure for foreign competitors entering the U.S. market without FTO clearance.